There are currently 442 clinical trials in Kansas City, Missouri looking for participants to engage in research studies. Trials are conducted at various facilities, including Children's Mercy Hospital, Research Medical Center, Saint Luke's Hospital of Kansas City and CCOP - Kansas City. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
NCT05500222
Recruiting
This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepatitis (NASH) cirrhosis by measuring the time to experiencing a Composite Clinical Outcome event.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2024
Locations: Kansas City Research Institute, Kansas City, Missouri
Conditions: NASH, Cirrhosis, Liver
Register for Updates
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
NCT06008197
Recruiting
Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients hospitalized with acute decompensated heart failure (HF) and mildly reduced or preserved left ventricular ejection fraction.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/29/2024
Locations: Kansas City, MO Investigative Site, Kansas City, Missouri
Conditions: Heart Failure, Acute Heart Failure
Register for Updates
The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers
NCT04781192
Recruiting
The purpose of this study is to measure how effective combining Durvalumab and Regorafenib will be for participants with advance stage biliary track carcinoma who have received one line of prior treatment
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/22/2024
Locations: University of Kansas Cancer Center - North, Kansas City, Missouri
Conditions: Advanced Biliary Tract Cancer
Register for Updates
Cognitive Behavioral Intervention to Reduce Procedural Anxiety Among Woman With High Risk Pregnancies With Scheduled Cesarean Deliveries
NCT04203082
Recruiting
The goals of this study are to determine the feasibility and efficacy of a brief, single-session cognitive-behavioral intervention for reducing preoperative and postoperative anxiety and for determining satisfaction with the delivery process in pregnant women scheduled for Cesarean delivery due to complications with their pregnancy. This will be done through a combination of psychoeducation and exposure therapy, where the participants will be walked through the steps of a Cesarean delivery in an... Read More
Gender:
FEMALE
Ages:
Between 18 years and 60 years
Trial Updated:
02/20/2024
Locations: Children's Mercy, Kansas City, Missouri
Conditions: Procedural Anxiety, High Risk Pregnancy, Fetal Complications
Register for Updates
Role of Novel ILR in the Management of PVCs
NCT06060548
Recruiting
This prospective, observational study is a single center clinical registry of patients referred for management of symptomatic or asymptomatic Premature Ventricular Contractions (PVCs). Subjects will be followed through 12 months. The study will enroll approximately 50 patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2024
Locations: Research Medical Center Clinic, Kansas City, Missouri +1 locations
Conditions: PVC - Premature Ventricular Contraction, Myocarditis
Register for Updates
Evaluation of Dupilumab in Patients With Atopic Keratoconjunctivitis (AKC)
NCT04296864
Recruiting
This is a multi-center, double-masked, randomized, placebo-controlled, parallel-group, efficacy, safety, and tolerability study evaluating the efficacy of Dupilumab in the treatment of signs and symptoms of atopic keratoconjunctivitis (AKC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2024
Locations: Silverstein Eye Centers, Kansas City, Missouri
Conditions: Atopic Keratoconjunctivitis
Register for Updates
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728
Recruiting
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: Saint Luke's Hospital of Kansas City, Kansas City, Missouri +1 locations
Conditions: NASH - Nonalcoholic Steatohepatitis
Register for Updates
An Efficient Treatment for Posttraumatic Injury for Firefighters
NCT05950035
Recruiting
The goal of this two-arm pilot randomized controlled trial is to test a behavioral intervention that integrates three evidence-based cognitive behavioral interventions (written exposure therapy; WET, cognitive behavioral therapy for insomnia; CBT-I, and cognitive behavioral therapy for nightmares; CBT-N) among firefighters. The main questions it aims to answer are: * Is the behavioral intervention feasible, acceptable, and effective in reducing symptoms of posttraumatic stress, insomnia, and ni... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/23/2024
Locations: NDRI_USA, Kansas City, Missouri
Conditions: Posttraumatic Stress Disorder, Insomnia, Nightmare
Register for Updates
Comparing Hypo-fractionated Intensity- Modulated Radiation Therapy to Standard- Fractionated IMRT Along With Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer
NCT04992780
Recruiting
The hypothesis for this study is that hypofractionated IMRT to 62.5 Gy in 25 fractions (2.5 Gy/fraction) with concurrent carboplatin and paclitaxel, followed by maintenance durvalumab will improve locoregional control at 18 months by 10% compared to standard-fractionated chemo-IMRT/durvalumab. A modest improvement in locoregional control (LRC) was selected as a target which could merit further study of this hypofractionated IMRT regimen in a Phase III trial
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2023
Locations: The University of Kansas Cancer Center, North Clinic, Kansas City, Missouri
Conditions: Non Small Cell Lung Cancer Stage
Register for Updates
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
NCT04951219
Recruiting
A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resmetirom (MGL-3196)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: Kansas City Research Institute, Kansas City, Missouri
Conditions: Non-Alcoholic Fatty Liver Disease
Register for Updates
ADPKD Patient Registry
NCT04039061
Recruiting
The purpose of the ADPKD Registry is to create an online patient network that includes at least 5,000 people with Autosomal Dominant Polycystic Kidney Disease (ADPKD) who contribute data on their health and other topics. The ADPKD Patient Registry aims to support important scientific discoveries and support patient needs in the following ways: * Connect ADPKD patients with opportunities to join clinical studies. * Collect data for the research community to better describe the ADPKD disease expe... Read More
Gender:
ALL
Ages:
All
Trial Updated:
11/15/2023
Locations: PKD Foundation, Kansas City, Missouri
Conditions: Polycystic Kidney Diseases
Register for Updates
Treatment of PAF With the Synaptic System
NCT05905835
Recruiting
Enrolled subjects will be treated with the Synaptic Cryoablation System. Treatment will include cryoablation of the pulmonary veins to achieve PVI. All subjects will be followed for twelve (12) months after completion of the index ablation procedure.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
11/09/2023
Locations: St. Luke's Mid America, Kansas City, Missouri
Conditions: Paroxysmal Atrial Fibrillation
Register for Updates